MedTrace Logo

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

NCT00018278 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2009-01-21

No results posted yet for this study

Summary

The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Aricept

DRUG

Exelon

DRUG

Nicoderm Patch

Sponsors & Collaborators

Principal Investigators

  • Vincente Iragui, M.D., Ph.D

  • Shuanna Morris, Ph.D.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-10-31
Completion
2001-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00018278 on ClinicalTrials.gov